Mihoko Yoshino

Mihoko Yoshino

Auto-generated profile, based on publicly available information

Mihoko Yoshino

Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
GSGordon I. Smith
Gordon I. Smith
MSMahalakshmi Shankaran
Mahalakshmi Shankaran
MYMihoko Yoshino
Mihoko Yoshino
GSGeorge G. Schweitzer
George G. Schweitzer
MCMaria Chondronikola
Maria Chondronikola
SKSamuel Klein
Samuel Klein
BACKGROUND. An increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear. METHODS. Hepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%. RESULTS. The contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations. CONCLUSIONS. These data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL. TRIAL REGISTRATION. ClinicalTrials.gov NCT02706262. FUNDING. This study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.

22 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
MYMihoko Yoshino
Mihoko Yoshino
JYJun Yoshino
Jun Yoshino
BKBrandon D. Kayser
Brandon D. Kayser
GPGary J. Patti
Gary J. Patti
MFMichael P. Franczyk
Michael P. Franczyk
SKSamuel Klein
Samuel Klein
Anti-aging supplement effects in humans: Synthesis of nicotinamide adenine dinucleotide (NAD + ) decreases during aging, which is thought to limit the activity of enzymes that require it for their catalytic activity. Studies in animals indicate that replenishment of cellular NAD + can have beneficial effects on aging and age-related diseases, but the situation in humans is less clear. Yoshino et al. report the effects of supplementation with the NAD + precursor nicotinamide mononucleotide in overweight or obese postmenopausal women with prediabetes (see the Perspective by Hepler and Bass). The treatment improved insulin sensitivity in muscle, although a change in NAD + content was not detected. The treatment also increased the expression of platelet-derived growth factor b. The results support potential therapeutic action of NAD + supplementation in humans, but how various NAD+ precursors are processed in specific tissues remains to be fully explored. Science , abe9985, this issue p. 1224 ; see also abj0764, p. 1147

1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GSGordon I. Smith
Gordon I. Smith
DPDavid C. Polidori
David C. Polidori
MYMihoko Yoshino
Mihoko Yoshino
MKMonica L. Kearney
Monica L. Kearney
BPBruce W. Patterson
Bruce W. Patterson
SKSamuel Klein
Samuel Klein
BACKGROUND. Insulin is a key regulator of metabolic function. The effects of excess adiposity, insulin resistance, and hepatic steatosis on the complex integration of insulin secretion and hepatic and extrahepatic tissue extraction are not clear. METHODS. A hyperinsulinemic-euglycemic clamp and a 3-hour oral glucose tolerance test were performed to evaluate insulin sensitivity and insulin kinetics after glucose ingestion in 3 groups: (a) lean subjects with normal intrahepatic triglyceride (IHTG) and glucose tolerance (lean-NL; n = 14), (b) obese subjects with normal IHTG and glucose tolerance (obese-NL; n = 24), and (c) obese subjects with nonalcoholic fatty liver disease (NAFLD) and prediabetes (obese-NAFLD; n = 22). RESULTS. Insulin sensitivity progressively decreased and insulin secretion progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups. Fractional hepatic insulin extraction progressively decreased from the lean-NL to the obese-NL to the obese-NAFLD groups, whereas total hepatic insulin extraction (molar amount removed) was greater in the obese-NL and obese-NAFLD subjects than in the lean-NL subjects. Insulin appearance in the systemic circulation and extrahepatic insulin extraction progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups. Total hepatic insulin extraction plateaued at high rates of insulin delivery, whereas the relationship between systemic insulin appearance and total extrahepatic extraction was linear. CONCLUSION. Hyperinsulinemia after glucose ingestion in obese-NL and obese-NAFLD is due to an increase in insulin secretion, without a decrease in total hepatic or extrahepatic insulin extraction. However, the liver’s maximum capacity to remove insulin is limited because of a saturable extraction process. The increase in insulin delivery to the liver and extrahepatic tissues in obese-NAFLD is unable to compensate for the increase in insulin resistance, resulting in impaired glucose homeostasis. TRIAL REGISTRATION. ClinicalTrials.gov NCT02706262. FUNDING. NIH grants DK56341 (Nutrition Obesity Research Center), DK052574 (Digestive Disease Research Center), RR024992 (Clinical and Translational Science Award), and T32 DK007120 (a T32 Ruth L. Kirschstein National Research Service Award); the American Diabetes Foundation (1-18-ICTS-119); Janssen Research & Development; and the Pershing Square Foundation.

1 February 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BMBettina Mittendorfer
Bettina Mittendorfer
BPBruce W. Patterson
Bruce W. Patterson
GSGordon I. Smith
Gordon I. Smith
MYMihoko Yoshino
Mihoko Yoshino
SKSamuel Klein
Samuel Klein
Background. It is unclear how excess adiposity and insulin resistance affect β cell function, insulin secretion, and insulin clearance in people with obesity. Methods. We used a hyperinsulinemic-euglycemic clamp procedure and a modified oral glucose tolerance test to evaluate the interrelationships among obesity, insulin sensitivity, insulin kinetics, and glycemic status in 5 groups of individuals: normoglycemic lean and obese individuals with (a) normal fasting glucose and normal glucose tolerance (Ob-NFG-NGT), (b) NFG and impaired glucose tolerance (Ob-NFG-IGT), (c) impaired fasting glucose and IGT (Ob-IFG-IGT), or (d) type 2 diabetes (Ob-T2D). Results. Glucose-stimulated insulin secretion (GSIS), an assessment of β cell function, was greater in the Ob-NFG-NGT and Ob-NFG-IGT groups than in the lean group, even when insulin sensitivity was matched in the obese and lean groups. Insulin sensitivity, not GSIS, was decreased in the Ob-NFG-IGT group compared with the Ob-NFG-NGT group, whereas GSIS, not insulin sensitivity, was decreased in the Ob-IFG-IGT and Ob-T2D groups compared with the Ob-NFG-NGT and Ob-NFG-IGT groups. Insulin clearance was directly related to insulin sensitivity and inversely related to the postprandial increase in insulin secretion and plasma insulin concentration. Conclusion. Increased adiposity per se, not insulin resistance, enhanced insulin secretion in people with obesity. The obesity-induced increase in insulin secretion, in conjunction with a decrease in insulin clearance, sufficiently raised the plasma insulin concentrations needed to maintain normoglycemia in individuals with moderate, but not severe, insulin resistance. A deterioration in β cell function, not a decrease in insulin sensitivity, was a determinant of IFG and ultimately leads to T2D. CLINICAL TRIALS REGISTRATION. ClinicalTrials.gov NCT02706262, NCT04131166, and NCT01977560. FUNDING. NIH (P30 DK056341, P30 DK020579, and UL1 TR000448); American Diabetes Association (1-18-ICTS-119); Longer Life Foundation; Pershing Square Foundation; and Washington University-Centene ARCH Personalized Medicine Initiative (P19-00559).

30 July 2021 in Science
Verified
Journal Article
Closed access
PDF file
SKSamuel Klein
Samuel Klein
MYMihoko Yoshino
Mihoko Yoshino
In evaluating any randomized clinical trial, it is important to determine whether baseline differences between groups could have affected the primary outcome. In our study, muscle insulin sensitivity, which was identical in both groups at baseline, improved after nicotinamide mononucleotide (NMN), not placebo, therapy. Differences in baseline intrahepatic triglyceride content between groups do not negate the effects of NMN observed in muscle.

1 February 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
RSRyo Suzuki
Ryo Suzuki
ALAndrea Leith
Andrea Leith
LHLewis Harrison
Lewis Harrison
YTYoshinori Tanizawa
Yoshinori Tanizawa
MUMoemi Urano
Moemi Urano
JMJulie Mount
Julie Mount
To describe the clinical characteristics, treatment approaches, and disease burden among older people with obesity disease (PwOD) in Japan. Secondary data from the Japanese cohort of the real-world, cross-sectional Adelphi Obesity Disease Specific Programme survey (July-December 2022) were analyzed. Physician's and PwOD's self-reported responses, including quality of life based on the Short Form Health Survey Version 2.0 (SF-36v2.0) and activity impairment from the Work Productivity and Activity Impairment (WPAI) questionnaire, were described by age group (<65 years, ≥65 years, and ≥75 years). Lower SF-36v2.0 scores (<45) and higher percentages in the WPAI questionnaire indicate greater impairment. Physicians (n = 101) provided data for 442 PwOD; 61 PwOD completed self-reported questionnaires. Older PwOD mainly consulted internal medicine physicians (≥65 years [45%] and ≥75 years [70%]). Common weight loss approaches across groups were: diets recommended and supervised by a healthcare provider (HCP)/dietitian/nutritionist/health coach; PwOD's own diet and exercise regime; and prescription obesity management medications. Physicians prioritized non-older PwOD for weight loss surgery or new weight loss drugs. In older PwOD, mean SF-36v2.0 physical component and bodily pain scores, and activity impairment were 34.5 (SD 12.8), 41.5 (SD 7.6), and 33.3% (SD 29.6%), respectively. Major weight loss goals in older PwOD were reducing joint pain and exercising regularly. Older Japanese PwOD faced physical impairments and were generally treated with lifestyle interventions by internal medicine physicians rather than specialists such as endocrinologists/diabetologists. HCPs should recognize obesity disease and obesity-related health disorders and provide appropriate medical care tailored to the specific needs of older PwOD.